Skip To Main Content
Shu Ying Mai on Muck Rack

Shu Ying Mai

As seen in: JD Supra, The National Law Review, Mondaq, LexBlog
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shu

Contact Shu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

USCIS Reverts To 180-Day Automatic Extension Of Employment Authorization For Certain Renewal Applicants

|
By Shu Ying Mai
| Mondaq
U.S. Citizenship and Immigration Services (USCIS) has ended its temporary 540-day automatic extension period for filing certain employment authorization documents (EAD). USCIS has reverted to the original 180-day period for certain renewal applicants with timely filed extensions of EADs on or after October 27, 2023, including those who have sought or obtained temporary protected status or asylum.
Open in Who Shared Issue with article?

USCIS Reverts to 180-Day Automatic Extension of Employment Authorization for Certain Renewal Applicants | JD Supra

|
By Shu Ying Mai
| JD Supra
U.S. Citizenship and Immigration Services (USCIS) has ended its temporary 540-day automatic extension period for filing certain employment authorization documents (EAD). USCIS has reverted to the original 180-day period for certain renewal applicants with timely filed extensions of EADs on or after October 27, 2023, including those who have sought or obtained temporary protected status or asylum.
Open in Who Shared Issue with article?

Ozempic Gains Popularity, Its Maker Loses First Legal Fight

|
By Keith Bishop, William E. Grob, Andrew B. Levin, Shu Ying Mai
| The National Law Review Verified
With Hollywood celebrities speaking out both in favor of and against the use of drugs like Ozempic and Wegovy for weight loss, it was only a matter of time before demand outpaced supply. Although most might believe that increased demand is a good problem to have, a recent case involving Ozempic shows that pharmaceutical companies with popular drugs might face increased competition, without the ability to obtain legal remedies against their competitors.
Open in Who Shared View Duplicates (5) Issue with article?
See all 14 articles